The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

A transplant immunome deep sequencing and screening platform defines a unique targetable epitope fingerprint of multiple myeloma.

Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, von Pein UM, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M. Blood. 2016 Mar 31. pii: blood-2015-10-676536. [Epub ahead of print] PMID: 27034429 [PubMed - as supplied by publisher] READ MORE

Posted: April 28, 2016

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Dunn TJ, Dinner S, Price E, Coutré SE, Gotlib J, Hao Y, Berube C, Medeiros BC, Liedtke M. Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4. PMID: 27040320 [PubMed - in process] READ MORE

Posted: April 28, 2016

Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.

Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Wang J, Robinson S, Guo XE, Lund T, Normolle D, Mapara MY, Weiss SJ, Lentzsch S. J Clin Invest. 2016 Apr 4. pii: 80276. doi: 10.1172/JCI80276. [Epub ahead of print] PMID: 27043283 [PubMed - as supplied by publisher] READ MORE

Posted: April 28, 2016

Page 30 of 87« First...1020...2829303132...405060...Last »